Compare AbbVie Inc (ABBV) vs KeyCorp (KEY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs KeyCorp — how do they compare? AbbVie Inc trades at $254.18 (market cap $449.91B), while KeyCorp trades at $22.62 (market cap $25.22B). The key difference: AbbVie Inc is far larger — about 17.8× KeyCorp's market cap, and KeyCorp pays the higher dividend (3.51%). Which is the better fit depends on your goals.
| ABBV | KEY | |
|---|---|---|
Market Cap | $449.91B | $25.22B |
Sector | Health | Financials |
52-Week High | $261.07 | $23.43 |
52-Week Low | $184.85 | $16.78 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | 3.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $252.92, down 0.72% on the day, with strong technical support at $251 and resistance at $258. The stock shows bullish momentum with recent earnings beats and a consensus analyst price target of $266.33. Revenue grew to $61.16B in 2025, though net margins compressed to 5.79%. Key growth drivers include Skyrizi and Rinvoq offsetting Humira declines, supported by positive Phase 2 data for ELAHERE in ovarian cancer (PRNewsWire, 2026-04-12).
Outlook remains positive with immunology portfolio strength and dividend growth, but risks include patent cliffs in the 2030s and high debt levels. Institutional buying and 68% analyst buy ratings suggest confidence, though valuation multiples like P/E of 124.83 warrant caution. Near-term catalysts include Q2 2026 earnings expected at $3.79 EPS.
KeyCorp (KEY) trades at $23.37, up 1.52% today, with a bullish technical signal and strong earnings momentum after three consecutive quarterly beats. The stock shows robust fundamentals with a P/E of 14.37, net income margin of 26.05%, and a new $3 billion buyback program. Recent news highlights its inclusion in dividend-focused strategies and potential for further earnings outperformance.
Outlook remains positive given analyst consensus of $29.55 price target and 60.79% buy ratings. Risks include volatile cash flows and banking sector sensitivity to interest rates, but capital returns and earnings growth support upside potential for investors seeking value and income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →
